Table 5.
Select Severe Adverse Events on Bevacizumab Monotherapy
| N (%) | |
|---|---|
| Patients Referred to the MSKCC Urgent Care Center | 35 (49%) |
| Total Visits to MSKCC Urgent Care Center | 78 |
| Patients Requiring Admission after Referral to Urgent Care Center | 27 (38%) |
| Total Admissions | 51 |
| Admissions likely related to Bevacizumab | |
| Bleeding | |
| Grade 2 | 3 |
| Grade 3 | 3 |
| Admissions possibly related to Bevacizumab | |
| Failure to Thrive | |
| Grade 3 | 7 |
| Admission unrelated to Bevacizumab | |
| Hypercalcemia | |
| Grade 3 | 10 |
| Grade 4 | 3 |
| Pain | |
| Grade 2 | 1 |
| Grade 3 | 10 |
| Fever/Infection | |
| Grade 3 | 4 |
| Shortness of Breathe | |
| Grade 3 | 4 |
| Grade 4 | 1 |
| Other | |
| Atypical Chest Pain - Grade 2 | 1 |
| Scheduled Surgical Procedure | 1 |
| Post-operative Lower Extremity Edema - Grade 2 | 1 |
| Nausea/Vomiting - Grade 3 | 1 |
| Elevated bilirubin - Grade 4 | 1 |